Back

Reduction in Hepatic Phosphatidylcholine Biosynthesis Promotes MASH Through Copper Deficiency

Welles, J. E.; Garifallou, J. P.; Gonzalez, M. V.; Santoleri, D.; Choudhury, F.; DeNicola, G. M.; Martin, R. W.; Jiang, C.; Kim, J.; Li, G.; Aki, Y.; Chang, C. J.; Li, D.; Wells, R. G.; Xiao, Y.; Zhang, J.; Lazar, M. A.; Brady, D. C.; Titchenell, P. M.

2026-05-14 physiology
10.64898/2026.05.13.723926 bioRxiv
Show abstract

Metabolic dysfunction-associated steatohepatitis (MASH) is a progressive liver disease for which the mechanisms linking lipid dysregulation to fibrosis remain poorly defined. Hepatic phosphatidylcholine (PC) content is reduced in MASH, but how this alteration drives disease progression is unclear. Here, we identify a role for copper (Cu) homeostasis as a downstream effector of impaired PC biosynthesis. Using single-nucleus RNA sequencing in complementary genetic and dietary mouse models, we found that reduced hepatic PC is associated with marked depletion of hepatic Cu and a concomitant increase in circulating Cu, indicating disrupted Cu distribution. Mechanistically, PC depletion impaired plasma membrane localization of the high-affinity Cu transporter CTR1 (SLC31A1) in hepatocytes, limiting Cu uptake. In human hepatic stellate cells, Cu promoted fibrogenic activation, whereas suppression of Cu import or pharmacologic inhibition of MAPK signaling attenuated fibronectin deposition. In vivo, liver-directed Cu supplementation restored hepatic Cu levels and reduced steatosis but failed to improve fibrosis. In contrast, pharmacologic Cu chelation with bathocuproinedisulfonic acid (BCS) reduced fibrosis without affecting inflammation. Together, these findings identify Cu redistribution as a consequence of impaired PC biosynthesis and implicate Cu-dependent signaling in stellate cell activation, fibrogenesis and MASH pathogenesis. Graphical Abstract O_FIG O_LINKSMALLFIG WIDTH=200 HEIGHT=141 SRC="FIGDIR/small/723926v1_ufig1.gif" ALT="Figure 1"> View larger version (39K): org.highwire.dtl.DTLVardef@144d748org.highwire.dtl.DTLVardef@91dd8corg.highwire.dtl.DTLVardef@683686org.highwire.dtl.DTLVardef@1d3a0da_HPS_FORMAT_FIGEXP M_FIG C_FIG

Matching journals

The top 7 journals account for 50% of the predicted probability mass.

1
Nature Communications
4913 papers in training set
Top 15%
12.1%
2
Cell Reports
1338 papers in training set
Top 3%
9.9%
3
Journal of Clinical Investigation
164 papers in training set
Top 0.3%
6.7%
4
Molecular Metabolism
105 papers in training set
Top 0.3%
6.7%
5
Journal of Hepatology
18 papers in training set
Top 0.1%
6.7%
6
eLife
5422 papers in training set
Top 18%
4.7%
7
Proceedings of the National Academy of Sciences
2130 papers in training set
Top 18%
3.9%
50% of probability mass above
8
JCI Insight
241 papers in training set
Top 2%
3.5%
9
Cell Reports Medicine
140 papers in training set
Top 2%
3.5%
10
Gastroenterology
40 papers in training set
Top 0.6%
3.5%
11
Cell Chemical Biology
81 papers in training set
Top 0.9%
3.2%
12
Cellular and Molecular Gastroenterology and Hepatology
41 papers in training set
Top 0.2%
2.7%
13
Science Advances
1098 papers in training set
Top 10%
2.7%
14
Nature Metabolism
56 papers in training set
Top 0.9%
2.5%
15
Science Translational Medicine
111 papers in training set
Top 3%
1.7%
16
Cell Metabolism
49 papers in training set
Top 1%
1.6%
17
EMBO reports
136 papers in training set
Top 3%
1.6%
18
Science
429 papers in training set
Top 16%
1.4%
19
EMBO Molecular Medicine
85 papers in training set
Top 3%
1.2%
20
Cell
370 papers in training set
Top 15%
0.9%
21
Nature Cardiovascular Research
28 papers in training set
Top 0.5%
0.8%
22
Hepatology
18 papers in training set
Top 0.3%
0.8%
23
The EMBO Journal
267 papers in training set
Top 5%
0.7%
24
Nature Immunology
71 papers in training set
Top 2%
0.7%
25
Circulation
66 papers in training set
Top 3%
0.6%